Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare
Lincare to distribute Vivos oral appliances through an exclusive nationwide agreement
LITTLETON, Colo., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS a leading medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, has signed a U.S. nationwide distribution agreement with Lincare, a leading supplier of in-home respiratory therapy products and services for approximately 1.8 million patients.
The agreement follows the successful conclusion of a distribution pilot with Lincare, and marks an important milestone in Vivos’ strategy to engage with leading durable medical equipment (DME) companies in the United States. Vivos has agreed that Lincare will have a six-month exclusivity to distribute certain designated Vivos devices.
Jeff Barnhard, CEO of Lincare, said, “We are pleased to offer oral appliances as an alternative treatment to our non-compliant CPAP patients. Finding the best solutions for our sleep apnea patients has always been a high priority for Lincare. We look forward to working alongside Vivos-trained dentists.”
Kirk Huntsman, Chairman and CEO of Vivos, stated, “Across the United States, hundreds of thousands of new CPAP units are rented or sold through DME companies each month. Lincare is one of the market leaders in this sector, and we are pleased to join forces with them in this pioneering initiative. It is well known that a sizable number of sleep apnea patients discontinue CPAP usage in search of alternative treatment options. This important collaboration between a national supplier of DME like Lincare and an innovative oral appliance company like Vivos will bring fresh solutions and relief to patients currently seeking alternatives. Our pilot trial allowed both parties time to work through the program logistics, including the development of a new Vivos proprietary software to manage DME patients and scale to a national level.”
Mr. Huntsman continued, “As we move forward, we see these types of agreements as a key component in Vivos’ quest to achieve positive cash flows over the next year. We are currently focused on extending the scope of our efforts with Lincare to the next five major markets, with additional markets to follow according to a rollout schedule over the next 6-12 months.”
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective in approximately 40,000 patients treated worldwide by more than 1,800 trained dentists.
The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method.
For more information, visit .
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including, without limitation, the results of Vivos’ collaboration with Lincare and the anticipated impact on Vivos’ sales and results of operations as described herein) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies that increase revenues, (ii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iii) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all and (iv) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Vivos Investor Relations Contact:
Julie Gannon
Investor Relations Officer
720-442-8113
